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Abstract
Background
Many atrial fibrillation patients eligible for oral anticoagulants are unaware of the presence of
AF, and improved detection is necessary to facilitate thromboprophylaxis against stroke.
Objective
To assess the effectiveness of screening for AF compared to no screening and to compare
efficacy outcomes of different screening strategies.
Materials and methods
Cochrane Central Register of Controlled Trials, EMBASE and MEDLINE from Jan 1, 2000 –
Dec 31, 2015 were searched. Studies employing systematic or opportunistic screening and
using ECG or pulse palpation in populations age�40 years were included. Data describing
study and patient characteristics and number of patients with new AF were extracted. The
outcome was the incidence of previously undiagnosed AF.
Results
We identified 25 unique (3 RCTs and 22 observational) studies (n = 88 786) from 14 coun-
tries. The incidence of newly detected AF due to screening was 1.5% (95% CI 1.1 to 1.8%).
Systematic screening was more effective than opportunistic: 1.8% (95% CI 1.4 to 2.3%) vs.
1.1% (95% CI 0.6 to 1.6%), p<0.05, GP-led screening than community based: 1.9% (95%
CI 1.4 to 2.4%) vs. 1.1% (95% CI 0.7 to 1.6%), p<0.05, and repeated heart rhythm measure-
ments than isolated assessments of rhythm: 2.1% (95% CI 1.5–2.8) vs. 1.2% (95% CI 0.8–
1.6), p<0.05. Only heart rhythm measurement frequency had statistical significance in a
multivariate meta-regression model (p<0.05).
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Conclusions
Active screening for AF, whether systematic or opportunistic, is effective beginning from 40
years of age. The organisation of screening process may be more important than technical
solutions used for heart rhythm assessment.
Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia with the prevalence esti-
mated at 2% of the total adult population[1]. Over the last two decades the prevalence of
reported AF has increased by 13% and epidemiological studies predict further increases related
mostly to the ageing of the society[2]. AF carries a substantial risk of thromboembolism, heart
failure and mortality[3]. These risks of complications related to AF can be substantially
decreased by introduction of appropriate treatment. This has been repeatedly demonstrated
for oral anticoagulants (OACs) and acute ischemic stroke[4,5]. The nonvitamin-K antagonist
OACs may further improve outcomes and decrease the risk of intracranial bleeding[6]. Due to
lack of symptoms a significant proportion of patients suffering from AF are unaware of their
arrhythmia[7].
Screening for AF aimed at early detection of asymptomatic individuals appears to be soim-
portant as it enables the implementation of an early intervention and changes the prognosis.
According to the current ESC guidelines opportunistic screening for AF is recommended in
patients >65 years with the use of pulse-taking or an electrocardiogram (ECG)[8]. The STRO-
KESTOP study findings suggest that systematic screening based on repeated short ECG
recordings results in satisfactory yield for AF detection in elderly individuals[9].
It is currently unclear which of these two screening methods is more effective in detecting
previously undiagnosed AF. Other factors might also influence the efficiency of the screening
process. First, different technical modalities may be employed for the screening, including
standard 12-lead ECG, various portable devices recording data other than 12-lead ECG and
pulse palpation. Second, organisation of the screening process may vary (GP-led vs. commu-
nity-based approach).
In this systematic review and meta-analysis we aimed to: (1) assess the effectiveness of active
screening for previously undiagnosed AF and (2) investigate various aspects of the screening
programme.
Methods
The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) flow diagram and checklist (S1 Table) [10]. Details of the protocol for this system-
atic review were registered on PROSPERO and can be accessed at https://www.crd.york.ac.uk/
PROSPERO/display_record.asp?ID=CRD42017067507
Literature search
Relevant studies were identified by searching multiple databases including Cochrane Central
Register of Controlled Trials, EMBASE and MEDLINE (PubMed). Keyword search terms
were ‘atrial fibrillation’ AND (‘mass screening’ OR ‘screening’ OR ‘detection’ OR ‘case find-
ing’) AND (‘pulse’ OR ‘electrocardiography’ OR ‘ecg’ OR ‘electrocardiogram’). Embase data-
base was searched as follows: #1 ’atrial fibrillation [definition] OR ’atrial fibrillation [Title/
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Abstract], #2 ’mass screening [definition] OR ’mass screening’ [Title/Abstract] OR ’screening’
[Title/Abstract] OR ’detection’ [Title/Abstract] OR ’case finding’ [Title/Abstract], #3 ’pulse
rate’ [Definition] OR ’pulse rate’ [Title/Abstract] OR ’electrocardiogram’ [Definition] OR
’electrocardiogram’ [Title/Abstract] OR ’electrocardiography’ [Title/Abstract] OR ’ecg’ [Title/
Abstract], #4 ‘#1 AND #2 AND #3’. Search terms for MEDLINE and EMBASE with corre-
sponding publication numbers can be found in the S1 Appendix. The search was constrained
to the period January 1, 2000 –Dec 31, 2015. No language or other limitations were applied.
Reference lists of all included papers were searched to identify potentially relevant articles, so
the Internet handsearching was performed.
Criteria for considering studies
All randomised controlled trials (RCTs) and observational studies comparing screening for
AF to no screening were eligible for inclusion. Studies with historical control and in which
there was only an intervention arm were also qualified. Case series and review articles were
excluded.
Eligible participants were men and women� 40 years living in community or attending
GP practices. People with implanted pacemaker or defibrillator likewise any specific groups
like athletes were excluded. Patients with previous stroke or TIA were considered only if they
constituted a proportion of the larger population. Patients with the prior diagnosis of AF were
excluded from the final number of newly diagnosed AF cases.
Studies eligible for inclusion compared systematic or opportunistic screening programmes
to no screening in the control or pre-intervention group. “No screening” was defined as a pas-
sive approach towards the diagnosis of AF. The latter indicating that the diagnosis was made
either incidentally or following presentation with symptoms of arrhythmia over the study
period. “Systematic screening” was defined as screening carried out in all people over a certain
age or in a particular sub-group. “Opportunistic screening” was defined as screening per-
formed in patients attending medical professional for another reason. The term “active screen-
ing” encompasses both systematic and opportunistic screening and means searching for AF in
opposition to passive case-finding in people with symptoms or signs of AF referred to here as
“no screening”. Screening might have been led by primary care physicians in their local prac-
tices (using their facilities) or taken place in community, i.e. in the form of health program, in
which different medical centres participated. A detection method of AF in the intervention
group could consist of pulse palpation, ECG (less than 12-lead and 12-lead) and the use of
some other wearable devices. The heart rate could be checked only once or repeatedly, and the
programme could be designed as a one- or multi-step process. The diagnosis of AF needed to
eventually be confirmed using 12-lead ECG interpreted by an appropriately trained GP or a
cardiologist.
The primary outcome was the incidence of previously undiagnosed AF as the result of
screening or the difference in the incidence between the intervention and control (pre-inter-
vention) group. The secondary outcomes comprised the identification of factors influencing
the effectiveness of screening, as well as the eligibility of newly detected AF for stroke throm-
boprophylaxis (assessed with the use of CHADS2 or CHA2DS2-VASc scales).
Data collection and analysis
Preliminary screening of retrieved abstracts in order to eliminate irrelevant studies was per-
formed by two authors (AS, PP). All except two authors (GL, PPo) assessed full texts for eligi-
bility. Multiple reports from the same study were identified. Data from published reports was
extracted using a prespecified data collection form. Data describing study and patient
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characteristics, number of patients in intervention and control arm, number and percent of
patients with new AF, median CHA2DS2-VASc score, percentage of patients scoring�2 and
data necessary to perform risk of bias assessment were extracted. Risk of bias assessment was
performed by two authors (AS, PP). Disagreements were resolved by discussion with all other
authors. Randomized controlled studies were assessed according to the Cochrane Collabora-
tion’s tool and in prospective cohort studies the Newcastle-Ottawa Scale was adopted.
For any individual study a risk difference was calculated. In single-arm studies the risk in
control group was assumed to be 0. An intention-to-treat analysis to estimate new AF inci-
dence was conducted, the denominator being all patients qualified to (be screened) who were
eligible and consented, even if differently assessed in original study reports.
The methodological (study design, quality) and clinical (population, setting, systematic vs.
opportunistic screening) heterogeneity was assessed. It was decided to perform meta-analysis
to estimate new AF incidence as a result of screening using data collected from all eligible stud-
ies and to address the heterogeneity in subgroup and sensitivity analysis. Statistical heterogene-
ity was evaluated with Cochran’s Q-statistic and quantified with the I2 statistic. Whenever tests
for heterogeneity revealed that variations between the studies were statistically significant
(P< 0.05 or I2� 50%), a random-effects model was used. Subgroup analyses were carried out
as follows: cut-off age: >64 vs.<65 years old, setting: GP vs. community, type of intervention:
pulse palpation vs. ECG, 12-lead ECG vs. less than 12-lead ECG, systematic vs. opportunistic
screening, heart rhythm measurement frequency: repeated vs. only once, randomized clinical
trials vs. observational studies. In addition, five potential sources of heterogeneity: age, screen-
ing setting, ECG vs. pulse palpation, systematic vs. opportunistic screening and heart rhythm
measurement frequency were tested by meta-regression in a multivariate meta-regression
model. In sensitivity analysis studies in which recruited participants had to have one of the fol-
lowing: AF or stroke risk factor, heart disease (coronary heart disease, congestive heart failure)
were excluded. Egger’s test and Begg’s funnel plot were used to evaluate the publication bias.
All statistical analyses were performed using Statistica version 12.0 (StatSoft, Tulsa, US) and all
tested P values < 0.05 were considered statistically significant.
Results
Details of the study selection are presented in Fig 1. Table 1 displays the characteristics and
outcomes of included studies. 25 studies that were included came from 14 countries. Partici-
pants were recruited from GPs (10 studies) or community (15 studies). Concerning the study
design, these included 3 randomized clinical trials [11–13], 4 prospective cohort studies with
randomization [9,14–16], 13 prospective cohort studies [17–29], 4 cross-sectional studies [30–
33], and one case-control study[34].The total number of participants was 88 786 with weighted
mean age of 58.6 and 46.4% were males. The lower age limit for recruitment varied widely
across studies with 13 studies limiting recruitment to> 64 years [9,11,12,14,15,17,22–
24,28,30]. In 5 studies [13,18,21,25,26] recruited participants had to have one of the following:
AF or stroke risk factor, coronary heart disease, congestive heart failure. The most common
exclusion criteria were: atrial fibrillation or atrial flutter, prior stroke, transient ischemic attack,
implantable pacemaker or defibrillator, terminal illness or severe cognitive impairment.
In 14 studies [9,11–16,20,23,26–29,33] screening was conducted systematically, whereas in
13 studies [11,12,17–19,21,22,24,25,30–32,34] it was done opportunistically. In the SAFE study
[11] there were two screening arms: systematic and opportunistic. Similarly, in the RCT Mor-
gan 2002 [12] systematic and opportunistic groups were compared. These were analysed
separately for the calculation of main outcome in subgroup analysis. Screening modalities
differed between studies: in 11 [11,13,16,19–21,23,27,29,33,34] it was a 12-lead ECG; in 9
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Fig 1. Details of the study selection. In total, 1056 articles were found. A primary screen of the abstracts resulted in the exclusion of 947 records. A further 82
were excluded based on the full-text review. This produced 27 articles that met inclusion criteria though representing 25 unique (3 RCTs and 22 observational)
studies.
https://doi.org/10.1371/journal.pone.0213198.g001
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Table 1. Characteristics and outcomes of included studies.
Study Country Study design Population
cut-off age (mean);
setting
Intervention N New AF
(%)
Smyth 2015 [17] Ireland Prospective cohort >64 years (75.1); GP Pulse palpation, repeatedly,
opportunistic
7262 55 (0.8)
Svennberg 2015
[9]
Sweden Prospective cohort,
randomisation
75–76 years (75.5); community Less than 12-lead ECG, repeatedly,
systematic
7173 218 (3.0)
Bury 2015 [14] Ireland Prospective cohort,
randomisation
�70 years (78); GP Less than 12-lead ECG, only once,
systematic
566 12 (1.2)
Turakhia 2015
[18]
USA Prospective cohort �55 years (69); outpatient clinic Less than 12-lead ECG (Zio wearable
patch-based
device), repeatedly, opportunistic
75 4 (5.3)
Benito 2015[13] Spain RCT (69), primary healthcare centre 12-lead ECG, repeatedly, systematic
(intervention group)
463 11 (2.4)
Lowres 2014 [30] Australia Cross-sectional � 65 years (76); community Less than 12-lead ECG, only once,
opportunistic
1000 15 (1.5)
Javed 2014 [22] UK Prospective cohort >65 years (69.7); GP Less than 12-lead ECG, only once,
systematic
6856 54 (0.8)
Van Mourik 2014
[23]
Netherlands Prospective cohort �65 years (75.5); GP 12-lead ECG, only once, systematic 389 7 (1.8)
Virtanen 2014
[15]
Finland Prospective cohort study,
randomisation
�75 years (79); community Pulse palpation, repeatedly, systematic 205 4 (1.9)
Clua-Espuny
2013 [16]
Spain Prospective cohort,
randomisation
>60 years; GP 12-lead ECG, only once, systematic 1043 23 (2.2)
Rhys 2013 [24] UK Prospective cohort �65 years; community Pulse palpation, only once,
opportunistic
573 2 (0.3)
Hendrikx 2013
[25]
Sweden Prospective cohort (69.8); GP Less than 12-lead ECG, repeatedly,
opportunistic
928 35 (3.8)
Wiesel 2013 [26] USA Prospective cohort >64
years or those with hypertension, diabetes,
congestive heart failure, or
previous stroke (67); GP
Less than 12-lead ECG (AF-BP
monitor), repeatedly, systematic
139 2 (1.4)
Frewen 2013 [27] Ireland Prospective cohort �50 years (63.8); community 12-lead ECG, only once, systematic 4890 45 (0.9)
Sanmartin 2013
[28]
Spain Prospective cohort �65 years; community Pulse palpation, only once, systematic 1532 17 (1.1)
Claes 2012 [31] Belgium Cross-sectional �40 years (59); community Less than 12-lead ECG, only once,
opportunistic
10
758
167 (1.6)
Schnabel 2012
[33]
Germany Cross-sectional (52.2); community 12-lead ECG, only once, systematic 5000 25 (0.5)
Doliwa 2009 [32] Sweden Cross-sectional Community Less than 12-lead ECG, only once,
opportunistic
606 6 (1.0)
Yap 2008 [29] Singapore Prospective cohort �55 years; community 12-lead ECG, only once, systematic 1839 16 (0.9)
Kim 2007 [34] Korea Case-control (49_median); community 12-lead ECG, repeatedly, opportunistic 16
568
61 (0.4)
Fitzmaurice 2007
[11]
UK RCT �65 years (75.3); GP 12-lead ECG, only once, systematic 4562 74 (1.62)
Pulse palpation, repeatedly,
opportunistic
4575 75 (1.64)
Minami 2007
[19]
Japan Prospective cohort (51); community 12-lead ECG, only once, opportunistic 722 5 (0.7)
Scalvini 2005 [20] Italy Prospective cohort (61); GP 12-lead ECG, repeatedly, systematic 7516 271 (3.6)
Rockman 2004
[21]
USA Prospective cohort >60 years (70.8); community 12-lead ECG, only once, opportunistic 610 3 (0.5)
(Continued)
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[9,14,18,22,25,26,30–32] less than 12-lead (1-3-lead) ECG; and in 7 [11,12,15,17,24,28] pulse
palpation, usually followed by ECG if the pulse was irregular. In 17 studies [11,12,14,16,19,21–
24,27–33] there was only one heart rhythm measurement performed, while in 10
[9,11,13,15,17,18,20,25,26,34] studies the rhythm was taken several times within a certain time
period.
Risk of bias in included studies
Overall quality of non-randomized studies was moderate, according to the Newcastle-Ottawa
Scale. In four studies [18,21,25,26] the population was not representative of the average popu-
lation. In one study [15] it was not possible to objectively confirm whether screening actually
took place. In two studies [27,34] it was possible to include patients with already known AF in
the main outcome assessment. In three studies [18,31,32]the diagnosis of AF was not con-
firmed in an objective or blinded fashion, i.e. by the 12-lead ECG interpreted independently
by a cardiologist. Only in eight studies [9,15,17,18,20,25,26,34], in which heart rhythm mea-
surements were being repeated, follow-up was considered long enough for outcome to occur.
In one study [23] the proportion of patients eligible for and agreeing to screening who actually
were screened did not exceed 80%. In two randomised trials [11,12] risk of bias assessed
according to the Cochrane Collaboration’s tool was relatively low and in one[13]–relatively
high. The details of risk of bias assessment are presented in the Tables A-D in S2 Appendix.
Effects of interventions
Newly identified AF. The incidence of newly detected AF was 1.5% (95% CI 1.1–1.8%)
(Fig 2). The hypothesis about the homogeneity of the studies was rejected therefore a random
effects model was implemented (Q = 534, p<0.05, I2 = 95.13%).
Age cut-off for screening. When screening was limited to participants from studies with
entry cut-off�65 years (mean age 67.2 years), the incidence was 1.5% (95% CI 1.0–2.0%) as
compared to 1.4% (95% CI 1.0–1.9%) among participants from studies where entry cut-off was
40–64 years (mean age 52.2 years). This difference was not statistically significant (Table 2).
Stroke risk. CHA2DS2-VASc score, which describes the risk of thromboembolic compli-
cations, was reported in 11 studies [9,13,14,16–18,24,27,30,31,33], in one study [25] CHADS2
score was calculated. In 9 studies [9,13,14,17,18,24,25,30,33] the stroke risk for previously
unknown AF was reported separately. In all 9 studies, median CHA2DS2-VASc score or
CHADS2 score was not lower than 2. A vast majority of patients with newly detected AF
(90.9–100%) scored�2, which made them eligible for OACs.
Screening setting. AF incidence was significantly higher in the GP setting than the com-
munity setting: 1.9% (95% CI 1.4–2.4%) vs. 1.1% (95% CI 0.7–1.6%), p<0.05 (Fig 3).
ECG vs. pulse palpation. Different screening techniques were compared one to each
other and no statistical differences were found whether pulse palpation or ECG was used as a
Table 1. (Continued)
Study Country Study design Population
cut-off age (mean);
setting
Intervention N New AF
(%)
Morgan 2002
[12]
UK RCT 65 to 100 years; GP Pulse palpation, only once, systematic 1499 39 (2.6)
Pulse palpation, only once,
opportunistic
1437 15 (1.0)
AF–atrial fibrillation, AF-BP–atrial fibrillation-blood pressure, ECG–electrocardiogram, GP–general practitioner, RCT–randomised clinical trial
https://doi.org/10.1371/journal.pone.0213198.t001
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primary screening modality (1.3% vs. 1.6%, respectively). 12-lead ECG was numerically worse
compared to strategies other than 12-lead ECG in identifying new AF cases, but this difference
again was not significant: 1.3% vs. 1.9%.
Systematic vs. opportunistic screening. The incidence of newly detected AF was signifi-
cantly higher in studies in which screening was organized in a systematic way in contrast to
studies where it was opportunistic: 1.8% (95% CI 1.4–2.3%) vs. 1.1% (95% CI 0.6–1.6%),
p<0.05 (Fig 4).
When studies were subdivided in relation to screening technique and screening organiza-
tional process, the differences, though not significant, tended to be greater between systematic
screening vs. opportunistic screening groups than between pulse palpation-based vs. ECG-
based groups (Table 2).
Single vs. repeated measurements. Studies in which heart rhythm was measured repeat-
edly within a certain time period as opposed to a single measurement reported significantly
higher new AF incidence: 2.1% (95% CI 1.5–2.8%) vs. 1.2% (95% CI 0.8–1.6%), p<0.05 (Fig 5).
Study design. The incidence of newly identified AF was not different in RCTs in compari-
son with observational studies: 1.8% (95% CI 1.0–2.5%) vs. 1.4% (95% CI 1.0–1.8%), p>0.05.
Fig 2. Meta-analysis of new AF incidence due to screening. Three randomized trials and 22 observational studies were included. The total number
of participants was 88 786. Heterogeneity was high at I2 = 95.13% (Q = 534, p<0.05). The incidence of newly detected AF was 1.5% (95% CI 1.1–
1.8%). AF—atrial fibrillation.
https://doi.org/10.1371/journal.pone.0213198.g002
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Sensitivity analysis
In sensitivity analysis we excluded studies in which recruited participants had to have either of
the following: AF or stroke risk factor, coronary heart disease, congestive heart failure
[13,18,21,25,26]. However, the incidence of new AF was grossly unchanged and equalled 1.4%
(95% CI 1.0–1.8%).
Meta-regression analysis
Results of the meta-regression analysis are presented in Table 3. Only heart rhythm measure-
ment frequency had statistical significance in the multivariate model (p<0.05).
Publication bias
Asymmetric Begg’s funnel plot of newly identified AF together with the result of Egger’s test
(p = 0.002) suggested the presence of publication bias. Using ‘‘trim and fill” method, four
potentially missing studies were imputed on the left side of the funnel plot, yielding an
adjusted risk difference of 1.2% (95% CI 0.8–1.5%) (Fig 6).
Discussion
In this systematic review and meta-analysis of contemporary studies, our principal findings
are as follows: (i) active screening for previously undiagnosed AF is more effective than no
screening in terms of detection of new cases of AF in various populations of patients above 40
years of age; (ii) the incidence of “silent” AF in the current study was 1.5% which is consistent
with the previous report [35]; and (iii), the organisation of screening process may be more
important than technical solutions used for heart rhythm assessment.
In the present meta-analysis we analysed results of 25 studies employing different screening
modalities and approaches. This allowed for the comparison of various aspects of the screening
process. Such assessment was not possible in earlier review by Moran et al.[36] due to strict
inclusion criteria resulting in analysis of only one randomized controlled trial. Two recent
Table 2. Results of subgroup meta-analysis.
Comparison Group 1 Number of
studies
Number of
participants
% AF
identified
Group 2 Number of
studies
Number of
participants
% AF
identified
p
Age >64 13 37 629 1.5 (1.0–
2.0)
<65 14 51 157 1.4 (1.0–
1.9)
>0.05
Setting GPs 12 35 273 1.9 (1.4–
2.4)
Community 15 53 513 1.1 (0.7–
1.6)
<0.05
ECG vs. pulse
palpation
ECG 20 71 703 1.6 (1.2–
2.0)
Pulse palpation 7 17 083 1.3 (0.6–
1.9)
>0.05
12-lead ECG vs. less
than 12-lead ECG
12-lead ECG 11 43 602 1.3 (0.8–
1.9)
Less than 12-lead
ECG
9 28 101 1.9 (1.2–
2.6)
>0.05
Systematic vs.
opportunistic
Systematic 14 36 816 1.8 (1.4–
2.3)
Opportunistic 13 51 970 1.1 (0.6–
1.6)
<0.05
Method of screening Pulse palpation
systematic
3 3 236 1.8 (0.7–
3.0)
Pulse palpation
opportunistic
4 13 847 1.0 (01–1.8) >0.05
ECG systematic 11 33 580 1.8 (1.3–
2.4)
ECG opportunistic 9 38 123 1.2 (0.6–
1.8)
HR measurement
frequency
Repeated 10 44 904 2.1 (1.5–
2.8)
Only once 17 43 882 1.2 (0.8–
1.6)
<0.05
AF–atrial fibrillation, ECG–electrocardiogram, GP–general practitioner
https://doi.org/10.1371/journal.pone.0213198.t002
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systematic reviews differed from our work due to higher age cut-off (�65 years) for patients
included in analysed studies or exclusion of non-randomized studies. Nonetheless, both
reviews reported superiority of screening comparing to no screening for detection of previ-
ously undiagnosed AF[37,38].
Superiority of the systematic approach in identifying previously undiagnosed AF was
shown in the subgroup analysis of the current meta-analysis. Interestingly, higher efficiency of
systematic vs. opportunistic screening did not depend on the age-cut off in meta-regression
analysis. It suggests that systematic screening programmes may also be effective when
addressed towards individuals younger than septuagenarians and octogenarians.
When comparing systematic and opportunistic approach it should be noted that the results
of SAFE trial questioned the cost-effectiveness of the systematic screening [11,39] performed
in broad group of patients age� 65 years. However, the analysis of STROKESTOP study
showed that if carried out in precisely targeted population (75 to 76-years-old) the systematic
approach may well be cost-effective[40].
In our analysis, we also divided analysed studies into two groups based on the age cut-off:
(1) below 65 years and (2) equal or above 65 years. This particular cut-off was chosen in accor-
dance to ESC guidelines[8]–recommendation based on the entry criteria and the results of
Fig 3. Subgroup meta-analysis of new AF incidence according to setting. New AF incidence was significantly higher in studies (n = 12) in which
screening was performed in GP setting compared to studies in which screening was done in the community (n = 15): 1.9% (95% CI 1.4–2.4%) vs.
1.1% (95% CI 0.7–1.6%), p<0.05. AF—atrial fibrillation.
https://doi.org/10.1371/journal.pone.0213198.g003
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SAFE study[11,39]. We found no difference in terms of the effectiveness of screening aimed at
patients� 65 in comparison to screening employing lower cut-offs of age. However, it must
be noted that actual mean age of participants in these two groups of studies while undoubtedly
different (52.2 vs. 67.2 years) was still relatively low. Furthermore, while shifting down the cut-
off age for the participation in screening programmes to values between 40 and 65 years might
result in a similar detection rate of new AF (and thus higher absolute number of new cases), it
might not necessarily be a cost-effective approach as significant proportion of patients below
65 years will not require oral anticoagulation due to low CHA2DS2-VASc scores[8]. This
aspect was not assessed in our analysis.
Of interest, we showed that GP-led screening (carried out in local practices by primary care
physicians) was more effective than screening performed in the community. This observation
was proven to be valid also in meta-regression analysis which suggests its independence from
other aspects of screening. Similar findings were reported in previous systematic review by
Lowres et al.[35] It remains to be found which characteristics of GP-led screening give this
strategy an edge over community based screening. Among them the specific features of indi-
viduals attending GP surgeries (e.g. concomitant diseases) might increase the detection rate of
previously unknown AF[41]. Regardless of the potential explanation, our results clearly
Fig 4. Subgroup meta-analysis of new AF incidence according to systematic vs. opportunistic screening. New AF incidence was significantly
higher in studies (n = 14) in which screening was organized in a systematic way in contrast to studies where it was opportunistic (n = 13): 1.8%
(95% CI 1.4–2.3%) vs. 1.1% (95% CI 0.6–1.6%), p<0.05. AF—atrial fibrillation.
https://doi.org/10.1371/journal.pone.0213198.g004
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suggest that the GP-led approach might be a preferable method for further screening pro-
grammes when compared to the community based initiatives.
Importantly, the majority of patients (90.9% to 100%) with previously unknown AF quali-
fied for the anticoagulation treatment because of high thromboembolic risk[8]. Introduction
of such therapy might be of particular clinical [4,5] and economic benefit [40] for these indi-
viduals and thus further reinforces the practice of active screening.
Also, the current meta-analysis shows a similar effectiveness of screening modalities based
on ECG comparing to pulse palpation when used as initial assessment of the cardiac rhythm.
Fig 5. Subgroup meta-analysis of new AF incidence according to single vs. repeated screening. New AF incidence was significantly higher in
studies (n = 10) in which heart rhythm was measured repeatedly as opposed to studies with a single measurement performed (n = 17):: 2.1% (95%
CI 1.5–2.8%) vs. 1.2% (95% CI 0.8–1.6%), p<0.05. AF—atrial fibrillation.
https://doi.org/10.1371/journal.pone.0213198.g005
Table 3. Results of meta-regression analysis.
Variable Regression coefficient Standard error Lower 95% CI Upper 95% CI p
Systematic screening (ref. opportunistic) 0.0064 0.0039 -0.0013 0.0141 0.103
ECG (ref. pulse palpation) 0.0052 0.0056 -0.0059 0.0162 0.360
Age >64 (ref. <65) 0.0013 0.0052 -0.0089 0.0115 0.803
Repeated HR measurement (ref. single) 0.0089 0.0043 0.0005 0.0173 0.037
GP (ref. community) 0.0062 0.0043 -0.0022 0.0147 0.146
https://doi.org/10.1371/journal.pone.0213198.t003
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While incidence of undiagnosed AF was slightly higher with ECG (1.6% vs. 1.3%), the differ-
ence was not statistically meaningful. It is a reassuring finding as pulse palpation, when per-
formed by appropriately trained personnel, is more widely available as a first step of screening
for AF than ECG. Additionally, we confirmed non-inferiority of ECG systems using less than
12-leads tracings comparing to standard 12-lead ECG. In fact, the incidence of newly detected
AF was numerically greater in studies employing simplified ECG recordings.
Carrying out the repeated testing increased the detection rate of new AF and in fact, heart
rhythm measurement frequency was the only variable that showed statistical significance in a
multivariate meta-regression model. It is worth to note that the review by Lowres et al.[35]
included studies that screened on only one occasion. Interestingly in STROKESTOP study
intermittent monitoring diagnosed 4 times as many individuals with new AF compared with
the initial ECG[9]. Patients with permanent AF may have already been diagnosed, whereas
paroxysmal AF is more problematic to detect with single time-point measurement, as patients
may be in sinus rhythm when screened. User-friendly features of less than 12-lead ECG sys-
tems make the simplified and repeatable ECG approaches a viable option for further screening
programmes for “silent” AF–especially in individuals with low-burden, paroxysmal AF.
Fig 6. Funnel plot of newly identified AF. Begg’s funnel plot of newly identified AF was asymmetric suggesting the presence of publication bias.
Open circles represent the imputed sudies to adjust the analysis for the effect of potential publication bias. AF—atrial fibrillation.
https://doi.org/10.1371/journal.pone.0213198.g006
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In contrast to ESC guidelines the UK National Screening Committee (NSC) does not advo-
cate population screening for AF[42] based on: (1) lack of high-quality evidence coming from
randomised controlled trials confirming that screening for silent AF saves lives or reduces
morbidity and (2) uncertainty whether risk of stroke in someone with screen-detected AF is
the same as in individual with AF detected due to clinical presentation. However, in large UK
cohort study[43] it was shown that patents with incidentally detected ambulatory AF are char-
acterized by high risk of stroke which can be significantly reduced (similarly as the risk of
death) by introduction of anticoagulation treatment as compared to no therapy. Thus, the Brit-
ish Cardiovascular Society issued a subsequent statement[44], in response to rather conserva-
tive recommendation of NSC, suggesting that it would be in the public interest to reconsider
their decision. We believe that results of our study (among other recent publications[37,38])
support the concept of wide screening for AF.
Limitations
Our study is not without limitations. First of all, the heterogeneity of analysed studies must be
appreciated. Secondly, only three studies[11–13] were performed in a randomized manner
and only these included control groups what may question the reliability of the results
obtained. In fact, a proportion of new AF diagnoses may be due to incidental findings or devel-
opment of symptoms within the screening period. Finally, we analysed the effectiveness of dif-
ferent aspects of the screening process only in relation to new cases of AF. Therefore, we were
not able to assess the incidence of patients with previously diagnosed AF who were not using
adequate anticoagulation. Recognition of such individuals may be clinically as important as
finding patients with newly identified AF.
Conclusions
In conclusion, this meta-analysis showed that active screening for undiagnosed AF is effica-
cious beginning from 40 years of age. Our results suggest that the organisation of screening
process (GP-led, systematic and repeated screening) is more important than technical solu-
tions used for the heart rhythm assessment.
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